Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. - Wikidata - awgldk - TriplyDB

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

http://www.wikidata.org/entity/Q38289739

about

Diagnostic Value of microRNA for Alzheimer's Disease: A Systematic Review and Meta-Analysis Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team A Practical Guide to Immunoassay Method Validation CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults.Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies.Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.Inhibition of γ-Secretase Leads to an Increase in Presenilin-1.A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.Amyloid-β Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission.Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer's disease diagnosis and prognosis.Gene suppression approaches to neurodegeneration.Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Tau-based therapies in neurodegeneration: opportunities and challenges.Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation.Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease.White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.

P2860

Q26768181-789FAEE9-C31D-492C-BBB4-386449BD6F3A Q26770708-C619749B-368F-499C-97CA-9133D40F8E66 Q26781451-18498BBD-30BD-4111-83CD-1B09FDA2DF1C Q28081678-9CE833B3-F1F7-4CE0-8606-C80A30C12B91 Q28082380-661901D2-237B-4608-86D9-83E58CDD1205 Q28595520-F891A7D1-0296-40D6-AB7A-216206BB11F1 Q30661695-F5211E10-9060-407B-A7C4-12BA13726BB6 Q31144959-3F20FFA0-C78A-407A-ACCB-72FA188464B5 Q33562458-30FD164C-9B98-4129-B827-13189F03D735 Q33587212-9C5D68B8-B2AC-4145-8537-F3207BCA57E3 Q36539454-D35DBFF3-B080-454F-B3CB-916FEF9C9CE6 Q37225128-BC2A361D-4558-427E-8F0A-52AC5CA0F600 Q38640436-0CE7494A-B5E7-40D3-B354-A60C7BA9D1BC Q38641308-08028A1A-0623-4A4E-A66F-68506A4DE47B Q38653383-4BD1C3E7-F1C5-4F01-BE04-004482B47319 Q38825497-3E25C835-B57C-463F-8093-AF08CB18663E Q38998886-3DEFBC1D-A69A-4621-BBD2-947B632A0864 Q39447075-1AD979F6-8443-4747-8B96-7B31FBE321D8 Q41025036-F6F10DA1-26F9-4F97-B148-F0C355A7E010 Q41845239-7DF8EC12-C287-4A13-A395-6606BB045E8B Q42371261-ADFCE2BF-821F-47A3-AEA8-C3E703492AD8 Q46240783-198ADF08-C504-47F3-8EDF-61D47E17C07A Q46390864-E552FC27-E567-4EB1-93E9-7AA55EC8F18B Q47587631-579664E3-1B42-411E-A44B-3699FBA73476 Q47689697-F2AA3301-1BE2-45D0-9B99-DC274E6065EB Q47878038-936A0E19-3A67-4F51-98B9-2489ED2D4E76 Q47937645-3A37C9F8-4706-4580-9FF5-245184E38792 Q48497489-64D508A9-3AAC-48BA-8AA4-0A4829774C64 Q48842795-4F541B7E-B858-4AC6-A51F-5172B0342B91 Q52801531-EBF4EEFA-65FE-4846-84F0-8F1F7A216C52 Q53396427-9E562DE5-5DA3-479E-AD2E-C701215F1E0B Q53396502-D8DF4740-2564-4583-B7B1-E03D2767A4B0 Q55383590-BCF05C9C-2905-4732-85EE-220B5D97C955

P2860

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

http://www.wikidata.org/entity/Q38289739

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

@en

type

label

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

@en

prefLabel

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

@en

P1433

Q38289739-E81F5DFA-141A-4E36-85E2-122DDCD7B4B8

P1476

Q38289739-5584E7C5-1E6E-43C4-9E61-5A7F49B14A03

P2093

Q38289739-100A8F90-4988-45E5-8357-3ED7FCBF7130

Q38289739-1F7B50FC-E199-45EC-B7FD-B662E5C3AA42

Q38289739-49D31CEF-C90C-4BFD-B023-C84F9A37E784

Q38289739-559A4439-C2BE-44A1-B39E-E8409A90A105

Q38289739-7647949B-148F-484E-9CA7-C3A28C2A2620

Q38289739-9FD983EC-56AE-4CC9-9D01-D41C2FE65F4D

Q38289739-D0136A0D-7872-4FA1-A48B-62B894D62BF8

Q38289739-E9F695A6-C4F9-497A-9856-BE7D1255C2CB

Q38289739-EBBADE3B-8353-43EC-B8ED-92B467E06665

Q38289739-FF6D0583-4E70-487F-8FE8-AAAD06A8C02E

P2860

Q38289739-00600E7F-D2F3-4CEA-BF6D-19EEEF73A038

Q38289739-00A23221-5A4A-4303-A7D0-739C187C8ACD

Q38289739-0320CA5C-3FAA-4987-BA57-E70B9959F182

Q38289739-0448CD29-CF01-4D88-A6A7-0474D32789EE

Q38289739-054B5D9C-FA51-41EF-81C6-31CB3D420BC4

Q38289739-05C683BD-6F5C-4290-92F1-1CF79E08601D

Q38289739-068FE32B-F769-40B3-B785-4BBA1EB5E173

Q38289739-0BB22F8A-23AF-49B0-BB0E-979754CB0C65

Q38289739-0C133EB0-B728-4746-A78B-933AB204699F

Q38289739-123662B7-19EE-45A2-9911-9FAEA6E3AEE1

P2888

Q38289739-87D2ECF8-8096-4420-A0D3-A9CE374757F4

P304

Q38289739-07C68FE9-0389-45BE-B63F-E0A0488285CE

P31

Q38289739-75F774E7-CB5B-491E-9969-D949B50D0082

P356

Q38289739-D1217E1E-CA37-401E-861B-60FFD5461D7A

P407

Q38289739-4B3D66F5-CC58-40B1-83C3-8D0FF92730CF

P433

Q38289739-CB7F9DC6-7D0A-409F-90A7-619433A67580

P478

Q38289739-3D016B5B-1C2F-43EE-9470-E75D4722D8A6

P50

Q38289739-022C0990-4E53-4787-A5CC-3455485A91D1

Q38289739-0E25F089-7EE3-4E2D-829B-D5A1D955DD6C

Q38289739-63505859-78DA-4BCE-9B8C-B5DE3AF66DEC

Q38289739-6453F098-0644-4B3A-9437-1F60D56F7D17

Q38289739-7EC7B36C-BEB0-4A8F-AD9F-9D68E771F948

Q38289739-8132C60B-D188-4E79-B384-EE27E20CB5B8

Q38289739-8B5EC96D-67D7-4F19-B73C-2524CCE1CB30

Q38289739-997B01DD-39B2-401E-9E89-696B3FF5C38D

Q38289739-9B306EDE-B6B3-4920-82F5-C9BF03A868E5

Q38289739-E339736C-523A-426D-8186-9C791E256500

P577

Q38289739-54DD1C1D-6226-49ED-A473-E39277EB8844

P6179

Q38289739-B29EED42-C0C3-48B1-8FF5-56F71414F714

P698

Q38289739-C082084B-C0F3-4291-87D8-15C49ABC65AC

P921

Q38289739-4BB14105-2B67-48D6-88A9-BEECA545751D

Q38289739-A1D35F38-C7F5-40F8-ACF1-7440BCC05198

Q38289739-AE172C68-86F4-4E8C-BC14-685098AC4A77

Q38289739-D3E9875F-C641-4B8C-9F14-8EC628C86881

P356

NRNEUROL.2014.232

P1433

Nature Reviews Neurology

P1476

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

@en

P2093

Alberto Lleó

http://www.w3.org/2001/XMLSchema#string

Andreas Jeromin

http://www.w3.org/2001/XMLSchema#string

Enrica Cavedo

http://www.w3.org/2001/XMLSchema#string

Hugo Vanderstichele

http://www.w3.org/2001/XMLSchema#string

Lucilla Parnetti

http://www.w3.org/2001/XMLSchema#string

Niels Andreasen

http://www.w3.org/2001/XMLSchema#string

Per Svenningsson

http://www.w3.org/2001/XMLSchema#string

Pieter Jelle Visser

http://www.w3.org/2001/XMLSchema#string

Piotr Lewczuk

http://www.w3.org/2001/XMLSchema#string

Sanna Kaisa Herukka

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

A window into the heterogeneity of human cerebrospinal fluid Aβ peptides

Alpha-synuclein in Lewy bodies

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Stages in the development of Parkinson's disease-related pathology

P2888

nrneurol.2014.232

P304

41-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRNEUROL.2014.232

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Brit Mollenhauer

José Luis Molinuevo

Roberta Ghidoni

Magda N. Tsolaki

Barbara Mroczko

Henrik Zetterberg

P577

2014-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021069106

http://www.w3.org/2001/XMLSchema#string

P698

25511894

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Parkinson's disease

cerebrospinal fluid